Kiniksa Pharmaceuticals International (KNSA) Free Cash Flow (QoQ) (2017 - 2026)
Kiniksa Pharmaceuticals International (KNSA) Free Cash Flow (QoQ) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.60 Bn | 87.73 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.81 Bn | 32.07 Bn | 1.97 Bn |
| 3 | Zoetis | 32.47 Bn | 30.53 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.55 Bn | 23.49 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.10 Bn | 20.95 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - |
| 7 | Viatris | 20.31 Bn | 18.50 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.77 Bn | 16.46 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn |
| 10 | Kiniksa Pharmaceuticals International | 4.94 Bn | 4.47 Bn | 193.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.58% |
| Dec 31, 2025 | 74.27% |
| Sep 30, 2025 | 2.22% |
| Jun 30, 2025 | 35.03% |
| Mar 31, 2025 | 141.34% |
| Dec 31, 2024 | 508.85% |
| Sep 30, 2024 | -144.36% |
| Jun 30, 2024 | 31.07% |
| Mar 31, 2024 | -56.75% |
| Dec 31, 2023 | -47.07% |
| Sep 30, 2023 | 340.06% |
| Jun 30, 2023 | -607.61% |
| Mar 31, 2023 | 91.35% |
| Dec 31, 2022 | -118.61% |
| Sep 30, 2022 | 680.05% |
| Jun 30, 2022 | 68.63% |
| Mar 31, 2022 | -54.93% |
| Dec 31, 2021 | 22.50% |
| Sep 30, 2021 | 27.21% |
| Jun 30, 2021 | 2.91% |